Odontoprev (ODPV3) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
21 May, 2026Executive summary
Revenues reached R$13.4 billion in 1Q26, with consolidated net income of R$1.3 billion and annualized ROAE of 24.8%, reflecting strong growth and scale in the healthcare ecosystem.
The ecosystem integrates health and dental insurance, hospitals, clinics, diagnostics, and technology, serving over 13 million beneficiaries nationwide.
Net additions totaled 193,000 in the quarter and 710,000 over the past 12 months, driven by commercial synergies and service expansion.
Major corporate restructuring completed, merging Bradesco Saúde, Odontoprev, and other assets under Bradsaúde, with the launch of the SAUD3 ticker.
Celebrated the launch of Bradsaúde's new IR website and new phase, highlighting integration and value generation over 20 years.
Financial highlights
Revenues reached R$13.4 billion in 1Q26, with net income of R$1.3 billion; Bradesco Saúde contributed 83%, Odontoprev 11%, Atlântica Hospitais 5%, and others 1%.
Financial assets totaled R$28.6 billion at the end of 1Q26, with financial results of R$875 million.
Written premiums for 1Q26 were R$13.3 billion, up 8.4% year-over-year; CAGR of 12.1% since 2021.
Odontoprev net revenue grew at a 15% CAGR since IPO, reaching R$2.4 billion in MAR26.
Net income for Odontoprev in 1Q26 was R$150.6 million, and for Bradesco Saúde R$914 million.
Outlook and guidance
Management remains cautious on claims ratio for 2026 due to seasonality, rising frequency, and medical inflation.
Continued expansion of hospital network with new openings scheduled through 2029, including Santa Lúcia Gama and Albert Einstein Vila Mariana.
Ongoing investments in technology, digital health, and innovation to enhance customer experience and operational efficiency.
Focus on sustainable cost management, price discipline, and long-term client retention.
Latest events from Odontoprev
- Membership and revenue growth fueled margin expansion and strong cash generation in 2025.ODPV3
Q4 20258 Apr 2026 - Record net income, margin expansion, and SME/Individual growth with strong cash position.ODPV3
Q3 20243 Feb 2026 - Record profitability, margin expansion, and 100% net income payout in 2Q24.ODPV3
Q2 20242 Feb 2026 - High-margin, tech-focused dental insurer grows SME segment, sustains top dividends, and zero debt.ODPV3
Status update28 Jan 2026 - Record recurring net income, margin expansion, and high payouts marked a strong 2024.ODPV3
Q4 20246 Jan 2026 - Record SME and Individual plan growth, margin expansion, and strong cash generation.ODPV3
Q2 202523 Nov 2025 - EBITDA margin rose to 38.3% in Q1 2025, led by SME and individual segment growth.ODPV3
Q1 202519 Nov 2025 - Record SME and Individual plan growth drove revenue, margin, and shareholder return gains.ODPV3
Q3 202513 Nov 2025